By Nick O'Brien
Last month, we launched a social media campaign to raise money for cancer research. We put out a call on our social channels, as well as here on the Medrio blog, for photos of our favorite cat, Dr. GoodData, pledging to donate a dollar to the UCSF Helen Diller Family Comprehensive Cancer Center for each … Read More →
By Nick O'Brien
In the time since our 2017 equity investment, one of Medrio’s central goals has been building out the resources to expand our existing international footprint. We established servers in Europe. We hired new staff in the Asia Pacific (APAC) region and elsewhere. And next month, from November 11 to 13, we’re heading to Tokyo for … Read More →
By Nick O'Brien
Contract research organizations have a fine line to walk. On one hand, they face the same mandate as anyone else involved with clinical research and drug development: delivering new treatments to market as rapidly as possible. This urgency has caused CROs to invest heavily in eClinical technology and other resources that unlock game-changing efficiencies, accelerating … Read More →
By Nick O'Brien
Clinical research looks much different today than it did just a few years ago. Whether it’s new approaches to clinical trial design, a surge in eClinical technology, or recent medical breakthroughs, the industry is under the influence of a wide array of forces driving its evolution. For CROs, some of the greatest impact has come … Read More →
By Nick O'Brien
This October, Fred Martin, Vice President of Product and Engineering at Medrio, will be at MAGI 2018 West to give a presentation and interface with industry professionals. Here’s Fred on his upcoming trip to San Diego for the conference. As we enter my favorite season (football, sweaters, autumn colors and the holidays), Medrio is approaching … Read More →
By Nick O'Brien
Precision medicine stands at the forefront of medical innovation. The growing focus on developing new drugs based on specific genetic biomarkers promises to revolutionize treatment, including in major fields like oncology, and improve outcomes for patients all over the world. In 2017, 35% of all new drugs approved by the FDA were personalized medicines, and … Read More →
By Nick O'Brien
Today’s blog post comes to us from Nathan Waller, Medrio’s Managing Director of EMEA and a former Director of Business Development at a Global CRO. If you know Medrio – if you’ve interacted with us at industry conferences, perused our site, or spend a good amount of time on this blog – you know that … Read More →
By Nick O'Brien
The clinical research industry is nothing if not regulated. To a significant degree, discussion about clinical research, whether in industry publications or CRO offices, centers around the regulatory side of things. And with the General Data Protection Regulation (GDPR) now in effect, there are even more regulatory standards to be discussed, managed, and navigated. But … Read More →
By Nick O'Brien
If you’ve read an industry publication in the past year, you probably read an article about electronic informed consent, or eConsent. It’s one of the hottest topics in the clinical trial space, and when we bring up that Medrio is finalizing the development of our eConsent tool, we always catch a lot of people’s attention. … Read More →
By Nick O'Brien
With a successful DIA 2018 behind us, the Medrio team has turned our attention to our next stop on the industry conference circuit: The Society for Clinical Data Management (SCDM) Annual Conference. This is a special time of year for us. While DIA offered a broad array of experts doing fascinating things across the healthcare … Read More →